Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human fibrinogen in congenital hypofibrinogenemia or afibrinogenemia
CTR20244863Phase 4Completed
- Sponsor
- Shanxi Kangbao Biological Products
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Fibrinogen human in congenital hypofibrinogenemia and congenital afibrinogenemia, sponsored by Shanxi Kangbao Biological Products. Primary endpoints: Hemostatic efficacy after first treatment for acute bleeding or perioperative bleeding and Activity recovery rate. Started Dec 2024; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
congenital hypofibrinogenemiacongenital afibrinogenemia
Beyond the preview
Go deeper on CTR20244863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244863.